Researchers in Oregon looked for discrepancies between published and unpublished FDA-registered trials. They found that four of the 24 FDA-registered trials of second-generation antipsychotics identified were unpublished. The mean effect size of the published trials was approximately double that of the unpublished trials. Results appeared this week in PLoS Medicine.
Article →
Related articles:
Washington Post
Medscape
Sydney Morning Herald
Fox News
Psych Central
ABC News
***
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
***
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.